BiomX Shares Phage Therapy Advances and Vision

BiomX ( (PHGE) ) has issued an announcement.

BiomX Inc., a clinical-stage biotechnology company, actively communicates with investors and provides updates on its business through presentations at various conferences and on its website. On September 26, 2024, BiomX updated its corporate presentation in the investors’ section of its website, highlighting its advancements in phage therapy for treating infections associated with chronic diseases. The company emphasizes the importance of addressing the growing challenge of antibiotic-resistant pathogens, and its presentation contains forward-looking statements regarding its clinical trials and the potential of its phage therapies. The information presented reflects the company’s status as of the presentation date and is subject to change without notice.

For detailed information about PHGE stock, go to TipRanks’ Stock Analysis page.